🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Genetic Study of Amyotrophic Lateral Sclerosis in Norway

Recruitingn/aAges 16 Years - 100 YearsAllSykehuset Telemark
NCT05119387 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to explore the genetic causes relevant for ALS development in Norway.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Probable or definite ALS * Eligible to consent Exclusion Criteria: \- not competent to give consent
💊

What it tests

  • Observation
📍

Where

17 sites
Haukeland University Hospital, Department of Neurology
Bergen, Norway
Nordland Hospital Trust, Department of Neurology
Bodø, Norway
Vestre Viken Hospital Trust, Department of Neurology
Drammen, Norway
Førde Hospital Trust, Department of Neurology
Førde, Norway
Østfold Hospital Trust, Department of Neurology
Grålum, Norway
Fonna Hospital Trust, Department of Neurology
Haugesund, Norway
Sørlandet Hospital Trust, Department of Neurology
Kristiansand, Norway
Innlandet Hospital Trust, Department of Neurology
Lillehammer, Norway

…and 9 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy